Table 5.

Time from study registration to report of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) by chemotherapy regimen received

Chemotherapy regimen	n	Median (mean) Years to AMLa	Min	Max	Standard deviation
AML events (n = 30)
AC	16	1.65 (2.67)	0.79	12.52	0.74
ACTb	13	2.48 (2.78)	0.88	6.98	0.44
CMF	1	7.26 (7.26)	7.26	7.26	–
MDS events (n = 17)
AC	7	2.74 (3.95)	2.03	7.84	0.83
ACTb	8	3.23 (3.47)	0.29	7.16	0.82
Capecitabine	1	2.22 (2.22)	2.22	2.22	–
CMF	1	5.87 (5.87)	5.87	5.87	–

AC doxorubicin and cyclophosphamide, ACT AC-paclitaxel, CMF cyclophosphamide, methotrexate, 5-fluorouracil

^aFrom study registration

^bIncluding all schedules of administration